MDGL - Madrigal Pharmaceuticals, Inc. - SEC Form 4 Insider Trading Screener

Manufactured Goods - Chemicals - Pharmaceutical Preparations - MDGL (1157601)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
 P - Purchase
 S - Sale
 A - Grant
 D - Sale to Iss
 G - Gift
 F - Tax
 M - Option Ex
 X - Option Ex
 C - Cnv Deriv
 W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title     Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10%own
  Other
Group by
Sort by
Max Results
Page
   clear
26 results. Finviz - SEC - Yahoo - Stockcharts - Tradingview
TCcnt1d1w1m6m

X

Filing Date

Trade Date

Ticker

Insider Name

Title

Trade Type  

Price

Qty

Owned

ΔOwn

Value

1d

1w

1m

6m

D
2024-06-14
MDGLWaltermire Robert E.SVP, Chief Pharma Dev.S - Sale+OE$280.00-1,9005,500-26%-$532,000
D
2024-06-12
MDGLWaltermire Robert E.SVP, Chief Pharma Dev.S - Sale+OE$285.00-2,0005,500-27%-$570,000
2024-05-21
MDGLWaltermire Robert E.SVP, Chief Pharma Dev.S - Sale$231.34-1,0365,500-16%-$239,668
D
2024-05-14
MDGLCraves Fred BDirS - Sale+OE$212.88-22,489489,685-4%-$4,787,404
D
2024-04-08
MDGLTaub RebeccaPres, R, D,, CMOS - Sale+OE$245.99-2,6761,114,5390%-$658,258
D
2024-04-08
MDGLFriedman Paul ADirS - Sale+OE$246.19-26,270841,275-3%-$6,467,491
DM
2024-04-03
MDGLTaub RebeccaPres, R, D,, CMOS - Sale+OE$243.92-73,8881,114,539-6%-$18,022,588
DM
2024-04-03
MDGLFriedman Paul ADirS - Sale+OE$243.93-73,730841,275-8%-$17,984,804
D
2024-04-01
MDGLLevy Richard SDirS - Sale+OE$257.49-11,00010,298-52%-$2,832,335
DM
2024-04-01
MDGLBate KennethDirS - Sale+OE$252.86-32,4891,198-96%-$8,214,998
DM
2024-04-01
MDGLDaly James MDirS - Sale+OE$252.97-32,4891,198-96%-$8,218,630
DM
2023-12-14
MDGLWaltermire Robert E.SVP, Chief Pharma Dev.S - Sale+OE$235.50-4,0005,667-41%-$942,000
M
2023-12-13
MDGLBaker Bros. Advisors LPDirP - Purchase$221.20+101,7921,793,403+6%+$22,516,577
2023-12-12
MDGLBaker Bros. Advisors LPDirP - Purchase$218.31+34,5781,699,129+2%+$7,548,616
DM
2023-12-12
MDGLWaltermire Robert E.SVP, Chief Pharma Dev.S - Sale+OE$222.82-3,8005,667-40%-$846,700
DM
2023-12-04
MDGLLynch Brian JosephSVP, GCS - Sale+OE$221.89-2,80015,531-15%-$621,294
DM
2023-11-29
MDGLLynch Brian JosephSVP, GCS - Sale+OE$201.50-7,00015,531-31%-$1,410,480
2023-11-21
MDGLBaker Bros. Advisors LPDirP - Purchase$188.48+64,3501,667,104+4%+$12,128,340
M
2023-11-17
MDGLBaker Bros. Advisors LPDirP - Purchase$178.11+67,0791,607,668+4%+$11,947,280
M
2023-11-14
MDGLBaker Bros. Advisors LPDirP - Purchase$158.13+49,3871,545,775+3%+$7,809,559
M
2023-11-13
MDGLBaker Bros. Advisors LPDirP - Purchase$146.99+107,4991,500,227+8%+$15,801,021
DM
2023-02-28
MDGLWaltermire Robert E.SVP, Chief Pharma Dev.S - Sale+OE$273.24-10,0005,667-64%-$2,732,438
D
2023-01-17
MDGLLevy Richard SDirS - Sale+OE$293.15-22,4899,100-71%-$6,592,686
D
2023-01-03
MDGLLynch Brian JosephSVP, GCS - Sale+OE$282.92-13,000530-96%-$3,677,977
D
2022-12-23
MDGLLynch Brian JosephSVP, GCS - Sale+OE$274.18-7,000530-93%-$1,919,231
D
2022-12-23
MDGLSukhija RemyChief Commercial OfficerS - Sale+OE$274.14-30,0000-100%-$8,224,073

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top